34results about How to "Therapy is also rapid" patented technology

Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.

The invention pertains to a dosage form 10 and to administering an antidepressant medicament 16 for an extended period of time in a rate-known dose.

The invention relates to a method for presenting interventional instruments in a 3D data set of an anatomy to be treated. A 3D data set of the anatomy is recorded before introduction of an interventional instrument. Once the interventional instrument has been applied, the spatial position of the instrument is determined by x-ray fluoroscopy from images created at two different angulations. A 3D model of the instrument is formed from the x-ray images. The 3D model of the instrument is fused with the 3D data set of the anatomy. A 3D hologram is reproduced from the fused 3D data set. The 3D hologram is repeatedly reproduced in real time to follow the application of the instrument in the presentation.

A number of protein and glycoprotein antigens secreted by Mycobacterium tuberculosis (Mtb) have been identified as “early” Mtb antigens on the basis early antibodies present in subjects infected with Mtb prior to the development of detectable clinical disease. Epitope-bearing peptide fragments of these early Mtb antigens, in particular of an 88 kDa secreted protein, GlcB (SEQ ID NO:106) and of Mtb antigen MPT51 (SEQ ID NO:107) have been identified. These peptides, variants thereof, peptide multimers thereof that include two or more repeats of one or more of the peptides, and fusion polypeptides that include early Mtb antigenic proteins, peptides or both, are useful in immunoassay methods for early, rapid detection of TB in a subject. Preferred immunoassays detect the antibodies in the subject's urine. Also provided are antigenic compositions, kits and methods to useful for detecting an early Mtb antibodies. The antigenic proteins and peptides are also used in vaccine compositions.

The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma.

The invention in some aspects provides methods of determining the likelihood that a subject has lung cancer based on the expression of informative-genes. In other aspects, the invention provides methods for determining an appropriate diagnostic intervention plan for a subject based on the expression of informative-genes. Related compositions and kits are provided in other aspects of the invention.

In one embodiment, the present application discloses a cell culture medium for culturing cell lines suitable for producing a therapeutic protein, comprising an amino acid selected from a group consisting of L-arginine, L-asparagine, L-proline, L leucine and L hydroxyproline and a mixture thereof; a vitamin selected from a group consisting of ascorbic acid Mg²⁺ salt, biotin, pyridoxine HCL, folic acid, riboflavin and D-calcium pantothenate, and a mixture thereof; an element selected from a group consisting of ammonium meta vanadate, sodium meta vanadate, germanium dioxide, barium acetate, aluminum chloride, rubidium chloride, cadmium chloride, ammonium molybedate, stannous chloride, cobalt chloride, chromium sulfate, silver nitrate, sodium metasilicate, zinc sulfate, manganese sulfate H₂O, manganous chloride, ferric nitrate 9H₂O, ferrous sulfate 7H₂O, ferric ammonium citrate, magnesium chloride anhydrous, and magnesium sulfate anhydrous, and a mixture thereof; a nucleoside selected from a group consisting of uridine and cystidine; a sugar selected from a group consisting of galactose, mannose and N-Acetyl-D-Mannosamine; and a triple buffering system comprising sodium carbonate, sodium bicarbonate and HEPES; wherein the cell culture medium is animal component-free, plant component-free, serum-free, growth factors-free, recombinant protein-free, lipid-free, steroid-free, and free of plant or animal hydrolysates and/or extracts.

The present invention relates to a method of preparing a composition for wound healing, and for repairing and regenerating human and animal tissue, said method comprising the following steps: a. providing a plasmid DNA in substantially pure form, which encodes a gene that has a positive effect on the progression of the regeneration of the tissue, b. providing a component/components of a self-hardening bio-polymer, and c. providing a cell suspension with cells which promote regeneration, characterized in that components (a), (b) and (c) are incubated with each other simultaneously or successively so that the plasmid and the cell suspension are obtained homogenously distributed in one of the biopolymer components. Furthermore, transfection systems containing a plasmid DNA, a component of a self-hardening biopolymer and a cell suspension with cells promoting regeneration are disclosed. This transfection system does not contain any further transfection-promoting or transfection-mediating substances. Moreover, therapeutical kits, pharmaceutical compositions and their use for the treatment of tissue defects, in particular burn wounds, and for wound healing in the skin are described. In particular, the present invention relates to a transfection system containing a plasmid DNA, a component of the fibrin adhesive and a cell suspension.

The present invention relates to a method of treating psychiatric symptoms in a subject having a NMDA receptor and a NE receptor which includes administering d-methadone, d-methadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, pharmaceutically acceptable salts thereof, or mixtures thereof, to the subject under conditions effective for the substance to bind to the NMDA receptor and NE receptor of the subject.

Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein.

Systems and methods for treating a patient having symptoms of restless legs syndrome (RLS) or Periodic Limb Movement Disorder (PLMD) using high-frequency stimulation by applying a high-frequency pulsed electrostimulation therapy signal to a peroneal nerve or a branch thereof, where the therapy signal is above a motor threshold of a muscle innervated by the peroneal nerve or branch thereof. Surface EMG (sEMG) response to neurostimulation can be used to evaluate patient responsivity to neurostimulation, or to evaluate neurostimulation efficacy, such as to compare various neurostimulation parameter settings and to select between such settings to meet or balance between one or more goals. The sEMG response can be obtained with the muscle at rest, or during muscle activation.

Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.

The invention relates to methods for osteogenic differentiation of human bone marrow stem cells (BMSC) or mesenchymal stem cells (MSC), in particular using human plasma or serum and FGF and TGFB growth factors. The invention also provides the so-obtained cells and cell populations, as well as further products comprising such and uses thereof in bone therapy.

A rapid contrast therapy system can provide cold, heat/hot/warm (hereafter referred to as “hot”), and/or rapid contrast therapy, which involves rapidly alternating between cold therapy and hot therapy. The system can circulate cold or hot fluid, such as water, through a hose, into a therapy wrap, and then back to the fluid reservoirs of the system. The system can utilize a vapor compression system or other chiller technology to cool the cold water reservoir, and immersion heaters can be used to heat the hot water reservoir.

Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.

The invention is a composition and method for treating acute pain using a composition containing one or more NSAIDs. The preferred composition includes ibuprofen, sodium bicarbonate, Gelucire, and tartaric acid

The invention, in general, features a method of treating a neurodegenerative disease (such as amyotrophic lateral sclerosis) or a traumatic brain injury in a subject (e.g., a human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of isolated B cells (such as autologous or allogeneic or xenogeneic B cells).